BIOHIT to present GastroPanel® Quick Test at IBMS Congress 2023

September 5, 2023

BIOHIT is pleased to announce its attendance at IBMS Congress 2023, where it will showcase its new GastroPanel^® Quick Test for triaging gastroscopy referrals. The prestigious annual event promises to be the UK’s largest biomedical science exhibition, and will feature over 300 lectures covering 13 medical disciplines, exploring the latest technological advances, products, services and equipment in the rapidly evolving field of laboratory medicine.

BIOHIT is taking this opportunity to present its newly launched GastroPanel Quick Test, a novel assay that enables the fast, first-line detection of Helicobacter pylori, atrophic gastritis and elevated stomach acid in both symptomatic and asymptomatic patients. This new diagnostics solution is designed to support rapid triage and referrals in primary care, helping to ensure timely endoscopy and treatment for patients at high risk of gastric cancer and other stomach conditions.

IBMS Congress 2023 will take place at the International Convention Centre in Birmingham from the 25^th to the 28^th of September. Come and talk to our expert team at Stand #817 throughout the event to discuss GastroPanel Quick Test, and how we can support a range of gastrointestinal diagnostics requirements.

About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health www.biohithealthcare.co.uk